Literature DB >> 12829150

Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.

Thomas F DeLaney1, Ira J Spiro, Herman D Suit, Mark C Gebhardt, Francis J Hornicek, Henry J Mankin, Andrew L Rosenberg, Daniel I Rosenthal, Fariba Miryousefi, Marcus Ancukiewicz, David C Harmon.   

Abstract

PURPOSE: Treatment of extremity soft-tissue sarcomas yields excellent local control, but distant failure is common with large, high-grade tumors. A regimen of preoperative chemotherapy consisting of mesna, adriamycin, ifosfamide, and dacarbazine (MAID) interdigitated with radiotherapy followed by resection and postoperative chemotherapy with or without radiotherapy was designed to improve treatment outcome. We report the mature outcome data on 48 treated patients and compare them with the data of an historical matched control patient population. METHODS AND MATERIALS: Adult patients with high-grade extremity soft-tissue sarcomas >or=8 cm were treated with three cycles of preoperative chemotherapy combined with 44 Gy of radiotherapy followed by surgery. Three cycles of postoperative MAID were planned. For patients with positive surgical margins, 16 Gy was delivered postoperatively.
RESULTS: All 48 patients (M0) received the MAID protocol treatment, and their outcome was superior to that of the historical control patients. The 5-year actuarial local control, freedom from distant metastasis, disease-free survival, and overall survival rate was 92% and 86% (p = 0.1155), 75% and 44% (p = 0.0016), 70% and 42% (p = 0.0002), and 87% and 58% (p = 0.0003) for the MAID and control patient groups, respectively. Acute hematologic toxicity in the MAID group included febrile neutropenia in 12 patients (25%). Wound healing complications occurred in 14 (29%) of 48 MAID patients. One MAID patient developed late fatal myelodysplasia.
CONCLUSION: After aggressive chemoradiation and surgery, these patients showed a significant reduction in distant metastases, with a highly significant gain in disease-free and overall survival compared with a historical control group. On the basis of this experience, the Radiation Therapy Oncology Group conducted a multi-institutional trial.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829150     DOI: 10.1016/s0360-3016(03)00186-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  77 in total

1.  Neoadjuvant radiation in primary extremity liposarcoma: correlation of MRI features with histopathology.

Authors:  Jeremy R Wortman; Sree Harsha Tirumani; Harika Tirumani; Atul B Shinagare; Jyothi P Jagannathan; Jason L Hornick; Nikhil H Ramaiya
Journal:  Eur Radiol       Date:  2015-08-28       Impact factor: 5.315

Review 2.  The diagnosis and treatment of soft tissue sarcomas of the limbs.

Authors:  Holger Bannasch; Steffen U Eisenhardt; Anca-Ligia Grosu; Jürgen Heinz; Arash Momeni; G Björn Stark
Journal:  Dtsch Arztebl Int       Date:  2011-01-21       Impact factor: 5.594

3.  Current treatment of soft tissue sarcoma.

Authors:  Shawn Steen; Gerald Stephenson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-10

4.  Soft tissue sarcoma clinical practice guidelines in oncology.

Authors:  George D Demetri; Laurence H Baker; Derrick Beech; Robert Benjamin; Ephraim S Casper; Ernest U Conrad; Thomas F DeLaney; David S Ettinger; Martin J Heslin; Ray J Hutchinson; Krystyna Kiel; William G Kraybill; G Douglas Letson; James Neff; Richard J O'Donnell; I Benjamin Paz; Raphael E Pollock; R Lor Randall; Karen D Schupak; Douglas S Tyler; Margaret von Mehren; Jeffrey Wayne
Journal:  J Natl Compr Canc Netw       Date:  2005-03       Impact factor: 11.908

5.  Evaluating the Role of Interdigitated Neoadjuvant Chemotherapy and Radiation in the Management of High-Grade Soft-Tissue Sarcoma: The Johns Hopkins Experience.

Authors:  Raju R Raval; Deborah Frassica; Katherine Thornton; Christian Meyer; David S Ettinger; Frank Frassica; Kristin Weber; Stephanie A Terezakis
Journal:  Am J Clin Oncol       Date:  2017-04       Impact factor: 2.339

6.  Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.

Authors:  Nicole J Look Hong; Francis J Hornicek; David C Harmon; Edwin Choy; Yen-Lin Chen; Sam S Yoon; G Petur Nielsen; Jackie Szymonifka; Beow Y Yeap; Thomas F DeLaney; John T Mullen
Journal:  Eur J Cancer       Date:  2012-10-22       Impact factor: 9.162

7.  A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas.

Authors:  Jörg Thomas Hartmann; M Horger; T Kluba; A Königsrainer; P de Zwart; C Hann von Weyhern; F Eckert; W Budach; C Bokemeyer
Journal:  Invest New Drugs       Date:  2013-10-04       Impact factor: 3.850

Review 8.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

9.  [Diagnostics and treatment strategies for soft tissue sarcomas].

Authors:  G Taeger; S Ruchholtz; J Schütte; D Nast-Kolb
Journal:  Unfallchirurg       Date:  2004-07       Impact factor: 1.000

Review 10.  Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.

Authors:  Cornelis Verhoef; Johannes H W de Wilt; Dirk J Grünhagen; Albertus N van Geel; Timo L M ten Hagen; Alexander M M Eggermont
Journal:  Curr Treat Options Oncol       Date:  2007-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.